Replies to post #42254 on SiNtx Technologies Inc (SINT)

[Atlanta1]

from the CFO posting: "Why Join SINTX Technologies?



· Opportunity to lead the financial function of a cutting-edge company at an exciting phase of growth.

· Collaborative and innovative culture with a commitment to making a meaningful impact in healthcare.

· Competitive compensation, equity opportunities, and a chance to influence the company’s future."

[joev2]

Someone needs to inform the big boys that this isn't blather of another sort. Considering there's not even 17k trading with 30 minutes left AND institutions would have been privy to a true changing element, methinks it's just the same old, same old.....

[boston745]

I post factual information here and on Teslas board on a daily basis, but im glad you appreciated this information. However this continues a positive trend of maneuvers made since November.

I'm back in based on this alone

Lets consider some other positive moves.
First was the buyback announcement of up to 20% which should be completed by Q2 or early Q3 2025 based on the use of the word "several" which implies more than 2 but not very many. 20% of the OS means that the float would drop to about 1m shares. I suspect that they bought back the majority of the shares on the day of the announcement given the sheer volume of shares traded.

SINTX Technologies Announces Stock Repurchase Program

Board of Directors has authorized a stock repurchase program to buy back up to $500,000 of the company’s outstanding common stock over the next several quarters which equates to about 20% of total outstanding shares.

Next they announced the hiring of Mr Honigblum as Chief Strategy Officer. Mr Honigblum aided Sintx in raising funds over almost the entire time it was a private entity stopping as soon as it went public. The fact that he is back and that the employee share plan was expanded, conveniently, suggests that hes going to aid in SINT valuation better reflecting the value of its tech and be rewarded for his years of service via issued shares.

SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer

n this role, Mr. Honigblum will oversee driving corporate strategy to support SINTX’s growth initiatives and enhancing investor relations.

Next thing to consider is Lind Partners Series E & F warrants. Specifically its Series F warrants. Those warrants have a strike price of $50 and expire August 2025. Thus for Lind to be able to utilize those warrants, one might think that SINT sees a price pump over $50 before August. As i already indicated, a float of 1m shares at that price, is only a valuation of $50m or so which Sintx is easily worth more than at current time based on its IP and partners. Hell its partnership with NedMedical is worth more than $50m by itself considering the microsphere cancer market is worth $5-15b. There are 3 products that could be released in a 2-5 year period for which they should already be a year into and product one being the easiest to bring to market. Products 2 & 3 will require trials and alot of capital.

The Class E and Class F Warrants were immediately exercisable at a price of $50.00 per share. The Class E Warrants expire five years from the date of issuance and the Class F Warrants expire eighteen months from the date of issuance.

Then of course there is NedMedical a wildcard in this. As far as i can tell so far, NedMedical has only raised a 1.8m seed round and was due for a Series A sometime Q1 2025 according to its CEO. Given Sintx and NedMedical's partnership, there is two distinct possibilities here, especially considering the product being created only works with Sintx ceramic microsphere technology. First Sintx could take an investment stake in NedMedical acquiring a portion of the company. The other is Sintx merges NedMedical into it as a subsidiary. Both of these scenarios require significant increase in valuation and cash for Sintx to manager either say a 20% stake or 50+% merger with Ned.

Given a Zimmer Biomet's board member's, i think son, is on Ned Medical's scientific board only supports these scenarios. Arthur Higgns, i believe to be dad, and NedMedical's Dr Luke Higgins, i believe to be the son.

What all this supports is SINT price increasing significantly this year if the August warrants are to be used and the fact that NedMedical is supposed to raise funds. In odd synchronicity, NedMedical is located outside of Boston which tickles me. Lots of reasons to be bullish but obviously timing is everything. Outside of calling a Tesla running a redlight and a solar storm a month before it happened, i dont have the greatest track record of predicting when something will happen. Still waiting for ZB to officially announce at least a partnership with Sintx.

Anyone can verify this factual information at the following links. My analysis is obviously mine but can be verified in previous posts to look for consistency as new information arises.

Sources:
https://ir.sintx.com/news-events/press-releases/detail/241/sintx-technologies-announces-stock-repurchase-program
https://ir.sintx.com/news-events/press-releases/detail/242/sintx-technologies-appoints-gregg-r-honigblum-as-chief
https://www.sec.gov/ix?doc=/Archives/edgar/data/1269026/000149315224044728/form10-q.htm
https://investor.zimmerbiomet.com/corporate-governance/board-of-directors/arthur-j-higgins
https://nedmedical.com/ned-medical-launches-world-class-scientific-advisory-board/

========================================

For continued coverage of significant Airplane malfunctions and why Sintx Si3N4 aerospace products are needed goto my research board. 24 plane malfunctions since December 22nd.
https://investorshub.advfn.com/Bostons-research-43724

Here is a collection of my research going over multiple subjects including Sintx connections with Zimmer Biomet, Solventum, Morgan Ceramics, & NP Aerospace. Includes other research topics as well.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175357996

========================================

We already know Sintx and Morgan were working together. If there is going to be some sort of NP/Sintx merger, that just solidifies it. We also know Zimmer Biomet and Sintx have had a long standing relationship (going on 20 years) so as long as Sintx components for Arthroplasty are any good, Zimmer Biomet will come out from behind the curtain. With ZB comes ZimVie and I believe Solventum because of Bryan Hanson. Leaving only Cardinal Health which is suggested by Sintx hiring of Joseph Palomo who joined Sintx from Cardinal Health R&D division.

Morgan Ceramics = Aerospace products
Zimmer Biomet = Arthroplasty oriented products
ZimVie = Dental?
Solventum = Wound Care, Catheters, & possibly Cancer treatment products.
Ned Medical = Microspheres for cancer treatment
Cardinal Health = PPE & Medical protection apparel.
NP Aerospace = Armor plates & other possible products connected to TA&T.

========================================

Markets Si3n4/Sintx Ceramics can be used in (not comprehensive)

Otho Market = $64 billion
Personal Protective Equipment market = $79.53 billion
Global Catheter market = $55bn
Antibacterial market = $44.5bn
Wound Care market = $22.25bn
Biosensors Market = $28.9bn
Condom Market = $11.6bn
Dental Implant market = $4.99bn
Armor Materials Market = $13.59bn
Cancer Treatment (microspheres) = $5-$15bn

Total = $330bn-340bn

Sources:
https://web.archive.org/web/2024040...ogger.blogspot.com/2011/05/whos-next.html?m=1
https://orthospinenews.com/2021/01/...y-2025-as-acquisitions-surge-says-globaldata/
https://www.grandviewresearch.com/industry-analysis/personal-protective-equipment-ppe-market
https://www.grandviewresearch.com/industry-analysis/catheters-market-analysis
https://www.grandviewresearch.com/industry-analysis/wound-care-market
https://www.grandviewresearch.com/industry-analysis/biosensors-market
https://www.grandviewresearch.com/industry-analysis/condom-market
https://www.mordorintelligence.com/industry-reports/armor-materials-market
https://www.grandviewresearch.com/industry-analysis/dental-implants-market
https://www.youtube.com/watch?v=KeSa5vCj6Kw
arch.com/industry-analysis/personal-protective-equipment-ppe-market
https://www.grandviewresearch.com/industry-analysis/catheters-market-analysis
https://www.grandviewresearch.com/industry-analysis/wound-care-market
https://www.grandviewresearch.com/industry-analysis/biosensors-market
https://www.grandviewresearch.com/industry-analysis/condom-market
https://www.mordorintelligence.com/industry-reports/armor-materials-market
https://www.grandviewresearch.com/industry-analysis/dental-implants-market
https://www.youtube.com/watch?v=KeSa5vCj6Kw